Evaluation of an educational telephone intervention strategy to improve non-screening colonoscopy attendance: A randomized controlled trial

Table 1 Baseline characteristics of the patients

	Intervention (n = 738)	Control (n = 746)	P value
Demographic variables
Age (yr), mean (SD)	59.1 (16.2)	59.9 (16.0)	0.307
Male sex, n (%)	347 (47)	363 (48.7)	0.527
Foreign nationality, n (%)	94 (12.7)	102 (13.7)	0.594
Advanced studies, n (%)	148 (20.1)	149 (20.0)	0.834
Language barrier, n (%)	67 (9.1)	53 (7.1)	0.163
Clinical variables
BMI, mean (SD)	26.7 (4.7)	26.9 (4.6)	0.657
Diabetes mellitus, n (%)	126 (17.1)	125 (16.8)	0.871
Abdominal/pelvic surgery, n (%)	287 (38.9)	292 (39.1)	0.920
Constipation, n (%)	148 (20.1)	161 (21.6)	0.469
Anxiety-depression syndrome, n (%)	253 (34.3)	253 (33.9)	0.881
Disabled condition, n (%)	29 (3.9)	33 (4.4)	0.634
Charlson index, mean (SD)	0.5 (0.9)	0.5 (0.9)	0.322
ASA classification III-IV, n (%)	84 (11.4)	100 (13.4)	0.237
High comorbidity burden, n (%)	33 (4.5)	42 (5.6)	0.308
Antiaggregants, n (%)
Aspirin	73 (9.9)	72(9.7)	0.798
Clopidogrel	6 (0.8)	9 (1.2)
Dual APA	1 (0.1)	2 (0.3)
VKA, n (%)	24 (3.3)	28 (3.8)	0.600
DOAC, n (%)
Rivaroxaban	4 (0.5)	4 (0.5)	0.735
Apixaban	8 (1.1)	(1.2)
Dabigatran	3 (0.4)	5 (0.7)
Endoscopic variables
Previous endoscopy, n (%)	335 (45.4)	323 (49.1)	0.417
Previous non-attendance, n (%)	77 (10.4)	86 (11.5)	0.500
Referring physician, n (%)
Primary care	668 (90.5)	684 (91.7)	0.128
Gastroenterologist	70 (9.5)	62 (8.3)
Indication, n (%)
Surveillance	211 (28.6)	197 (26.4)	0.620
Diagnostic	456 (61.8)	(63.3)
Family history of CRC	71 (9.6)	77 (10.3)
Waiting time (d), mean (SD)	60.7 (56.6)	59.5 (60.9)	0.701
Afternoon timetable, n (%)	467 (63.3)	746 (67.3)	0.104
Laxative, n (%)
MCSP	102 (15.1)	80 (12.5)	0.372
PEG + ascorbate, 2 L	158 (23.4)	3.2)
PEG, 4 L	416 (61.5)	411 (64.3)
Previous cleansing problems, n (%)	37 (5)	44 (5.9)	0.453

BMI: Body mass index; ASA classification: American Society of Anaesthesiologists classification; APA: Antiplatelet agent; VKA: Vitamin K antagonist; DOAC: Direct oral anticoagulant; CRC: Colorectal cancer; MCPS: Magnesium citrate plus sodium picosulfate; PEG: Polyethylene glycol.